Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion - Episode 9

CSU Burden of Disease and Quality of Life

Published on: March 6, 2025

Giselle Mosnaim, MD, MS , Shyam Joshi, MD , Mark Lebwohl, MD, Jason Hawkes, MD, MS

Panelists discuss how chronic spontaneous urticaria (CSU) significantly impacts patients’ quality of life through persistent itching, unpredictable flares, sleep disruption, emotional distress, and daily activity limitations, underscoring the need for effective disease control.

EP. 1: Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion

EP. 2: Pathophysiology of Chronic Spontaneous Urticaria

EP. 3: Current CSU Treatment Approach and the Role of Bruton Tyrosine Kinase

EP. 4: BTK Inhibition as a Strategy for CSU Treatment

EP. 5: How BTK Inhibitors Differ From Current CSU Treatment Approaches

EP. 6: Overview of BTK Inhibitors in Development for CSU Treatment

EP. 7: Differentiating BTK Inhibition From Genetic BTK Deficiency

EP. 8: Overview of Remibrutinib Phase 3 Clinical Trials in CSU

Now Viewing

EP. 9: CSU Burden of Disease and Quality of Life